Group items tagged

If you have recently been diagnosed with hearing loss, you may be feeling overwhelmed and unsure of what to do next. You are not alone - millions of people around the world are living with hearing loss. The good news is that there are many resources available to help you learn how to manage your condition and live a full life. In this blog post, we will discuss some of the most common issues that people with hearing loss face and provide tips on how to handle them. HANDLING ISSUES FROM HEARING LOSS - HOW TO DO IT PROPERLY Hearing loss is certainly a difficult obstacle to face in life, but it doesn't have to stop you from living a full and rich life. Of course, hearing loss comes with its own set of unique challenges, but there are ways to manage them. From learning what hearing aids are the best for you to communicate with loved ones, to the different types of therapies available, we're here to help you find the answers you need. Generally speaking, there are four main issues that people with hearing loss face; Isolation, communication difficulties, feeling overwhelmed and frustrated, and depression. Unfortunately, each of these "consequences" will likely get worse if hearing loss is not managed early on. Here are some tips on how to handle each one:

Boots has partnered with Uber Eats to deliver beauty essentials and healthcare products to customers' doors in 30 minutes. Medicines for minor ailments such as coughs, colds, hay fever, mild pain, rashes as well as COVID-19 test kits can be ordered through Uber Eats. Boots is partnering with the doorstep delivery company with a pilot in 14 of its stores around the UK, with 13 of those stores giving customers within range access to third-party doorstep delivery of Boots products for the very first time. Uber Eats customers within range of participating Boots stores can choose from more than 900 products available for delivery straight to their homes or workplace, including toiletries, medicines for minor ailments, food and drink options, and best-selling beauty and gifting options perfect for a last-minute gift or treat. Paula Bobbett, Chief Digital Officer at Boots said: "We are hugely excited to be launching our partnership with Uber Eats. As the first health and beauty retailer on its platform, we can offer an extensive range of product options to customers for delivery straight to their door. Whether it's medicines for mild illnesses or last-minute gifts, beauty items or top-ups of a favourite skincare brand, we can meet all our customers' needs both quickly and conveniently."

Glenmark, a multinational pharmaceutical company, has partnered with AI data-driven supply chain management platform 7bridges. Initially focusing on their European business, where they have operations in 15 markets, the supply chain and logistics function is a big focus area for this cost reduction. The partnership with 7bridges will allow Glenmark to baseline their supply chain data giving them visibility of data, cost and service performance across their network of logistics service providers. This exercise will identify areas where invoices from their logistics service providers are being incorrectly or overcharged. With automatic dispute raising, savings will be quickly achieved. The platform will then enable Glenmark to benchmark their data, so they can compare the performance and cost of their LSPs to the wider industry. With Glenmark's global vision to emerge as a leading integrated research-based global pharmaceutical company, this investment in their supply chain will be integral to achieving this. The next step in the partnership will be to run simulations to optimise road freight services and 3PL operations, with the aim to then roll out globally.

An experimental Alzheimer's drug developed by Eli Lilly and Co slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease. Lilly's drug, donanemab, met all goals of the trial, the company said. It slowed progression of Alzheimer's by 35% compared to a placebo in 1,182 people with early-stage disease whose brains had deposits of two key Alzheimer's proteins, beta amyloid as well as intermediate levels of tau, a protein linked with disease progression and brain cell death. The study also evaluated the drug in 552 patients with high levels of tau and found that when both groups were combined, donanemab slowed progression by 29% based on a commonly used scale of dementia progression known as the Clinical Dementia Rating Scale (CDR-SB). Using that scale, experts said Lilly's findings were roughly on par with Eisai Co Ltd and Biogen Inc's lecanemab, sold under the brand name Leqembi, which reduced cognitive decline by 27% in patients with early Alzheimer's in a study published last year. The results drove Lilly's shares to a record high, up more than 6% at $429.85. Dr. Ronald Petersen, an Alzheimer's researcher at Mayo Clinic, said Lilly's trial is the third to show removing amyloid from the brain slows progression of the disease, which could put to rest some lingering doubts about the benefits of drugs in the class and the amyloid-lowering theory. "It's modest, but I think it's real," he said of the benefit, "and I think it's clinically meaningful." Dr. Erik Musiek, a Washington University neurologist at Barnes-Jewish Hospital, said the efficacy looks as good or better than lecanemab.

AstraZeneca said on Monday (June 27) two of its existing therapies were recommended for treating patients with some forms of high-risk breast cancers in the European Union, in a boost to the company's oncology portfolio. Lynparza, a cancer drug developed jointly with U.S.-based Merck, was backed for standalone use or in combination with endocrine therapy in adults with a form of genetically mutated early-stage breast cancer. The drug, which has received a similar recommendation in the United States in March, is a key asset for AstraZeneca. It was recommended in patients with low-to-normal levels of a protein known as HER2 that is the target of several new therapies. Enhertu - developed jointly with Japan's Daiichi Sankyo (4568.T) - was the other drug that was endorsed by the European Medicines Agency for treating an aggressive form of breast cancer characterised by a high rate of HER2.

A 14-year-old heart transplant campaigner visited Phoenix UK's headquarters in Runcorn recently to raise awareness of the importance of organ donations. The visit by Max Johnson, founder of 'Max and Keira's law', along with his mother Emma, coincided with the launch of Phoenix UK's partnership with the British Heart Foundation (BHF) in which the pharmaceutical provider committed to set a donation goal of raising £20,000 by June 2023 for the heart charity. Max and Emma met with Phoenix UK's employees and gave a talk on the importance of the work they have carried out on behalf of BHF. Max, who was diagnosed with dilated cardiomyopathy when he was eight years old, also shared his own story. His life was saved when he was gifted with Kiera Ball's heart - a nine-year-old girl from Devon who died in a car accident. Max and his family campaigned tirelessly to change the law in England in favour of an opt-out system for organ donation since he was 'gifted' his new heart. 'Max and Keira's Law' passed in May 2020.

The National Institute for Health and Care Excellence (NICE) has recommended pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel) which is said to benefit people with triple negative breast cancer. Clinical trial evidence shows that, compared with paclitaxel, pembrolizumab combination increases how long people have before their cancer gets worse and how long they live. NICE already recommends atezolizumab in combination with chemotherapy for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer. Atezolizumab combination is recommended by NICE for people with IC equal to or greater than 1%. "This means that some people who can't have atezolizumab combination could be eligible for pembrolizumab combination," said NICE. NICE's independent appraisal committee also agreed that the pembrolizumab combination meets the higher cost-effectiveness threshold for life-extending treatments for people with a short life expectancy. Given by injection every 3 weeks, pembrolizumab (also called Keytruda and made by Merck Sharp and Dohme) is a type of immunotherapy that specifically targets triple negative breast cancer. It works by blocking the activity of a protein known as PD-L1 which is produced in larger amounts on cancerous cells than normal cells. By blocking PD-L1 it helps the person's own immune cells to attack the cancer.

Type 1 diabetes patients can monitor their glucose with the newly introduced flash glucose monitors by the NHS. The wearable gadgets with the size of a £2 coin, have a sensor that easily sits on the arm, allowing patients to check their glucose levels with a one-second scan. Eligible patients are currently able to access the monitors on prescription from their local GP or diabetes team, helping them to better manage their blood sugar levels. Everyone living with type 1 diabetes will be eligible for lifechanging flash glucose monitors on the NHS. The NHS Long Term Plan has already helped almost three in five people with Type 1 diabetes to access the monitors that allow people to check their glucose levels more easily and regularly. The change, confirmed today by the National Institute for Health and Care Excellence (NICE), means that everyone in England with the condition will be able to benefit from the convenient technology.

The Pharmaceutical Services Negotiating Committee (PSNC) has called the 'new general practice contract' which was imposed by NHS England on Monday (6 March) as 'simply unreasonable'. The imposition of new contract followed a failed talk of British Medical Association (BMA)'s with the negotiator. The association's main issue with the contract is the lack of further funding beyond that agreed in 2019 as part of the five-year deal. PSNC Chief Executive Janet Morrison said: "The breakdown in GP contract negotiations for the second year running is another blow for primary care. The verdict of the GP negotiators is that the demands being made of doctors by Government and the NHS are simply unreasonable." "Community pharmacy is being treated with the same disregard: too much is being asked of us, with far too little funding available." The committee has been raising the issue and challenges faced by the community pharmacists with the government. The government is asking pharmacies to do more by taking giving additional services but the committee is of view with no extra funding the community pharmacies will collapse.

A roundtable organised by National Pharmacists Association (NPA) discussed how an enhanced role of community pharmacies could help people with obesity. Seven action points were recommended by the delegates at the virtual event which took place on March 31, in collaboration with Novo Nordisk. It was chaired by Professor Maggie Rae, president of the Faculty of Public Health and featured representatives from the Royal Pharmaceutical Society, Royal Society for Public Health, Patients Association, UK Health Security Agency, Diabetes UK and NHS England. The roundtable also heard testimony from a parent of a young adult living with obesity and a presentation of the personal experience of someone living with the condition by Sarah Le Brocq, director of campaign group, All About Obesity.

Alitam has announced that it has merged with clinical skills training provider MHRx to upskill UK pharmacists so that its chain of community pharmacies in the UK can diagnose and treat minor medical ailments "quickly and safely". This is a second merger deal announced by the group that has 100-plus pharmacies, just days after its merger with Pharmadoctor to "radically transform the UK and Ireland's community pharmacy sector" into a truly preventative healthcare system. Following the merger with MHRx, Alitam will now be providing a career development platform for its pharmacy teams, which also include nurses and other healthcare professionals. MHRx's training incorporates every aspect of general practice alongside relevant topics including making appropriate patient consultation records in line with NHS guidelines. This, Alitam believes, will allow community pharmacies to carry out formal diagnoses, formulate differential diagnosis plans, and perform full clinical examinations. According to the founder and CEO Feisal Nahaboo, mergers such as these will lead to "a healthcare revolution predicated on building the world's first truly preventative healthcare model".

Two weeks prior to the closing of the hub and spoke consultation, issues around patient safety, costs and competition as well as practicalities such as what to do with uncollected medicines were discussed in a webinar on hub and spoke dispensing on Wednesday (May 26). The webinar was organised by Sigma Pharmaceuticals in association with the National Pharmacy Association (NPA). NPA director of corporate affairs Gareth Jones chaired the event and was joined by Sigma's Hatul Shah and Raj Haria as well as NPA vice chair Nick Kaye and NPA head of advice and support services Jasmine Shah. Kaye said: "There are still many 'unknown unknowns' with hub and spoke and the jury's still out on any potential benefits. I have lots of reservations about cost and it worries me how efficient this is for the business and the long term sustainability for the sector as a whole. Above all we need to think about the patient at the centre of all this and the potential confusion for them." Jasmine Shah felt patient safety was going to be the key in regards to whether the spoke and the hub would hold the ultimate responsibility and "who is going to take the accountability as far as patient care goes". She added: "It is most important that GPhC standards and NHS requirement are both met in identifying all the risks associated with the arrangement with hub and spoke and ensuring that (patient safety) measures are in place. Everything that needs to be looked at is by putting the patient at heart of the arrangement and seeing what is the safest way for them to receive care from both spoke and hub."

Following centuries of stigma, the importance of mental wellness is finally matching that of physical healthcare. Conditions such as depression have become common topics in the media, particularly in the last few years as celebrities and experts warned against the pressures of social media. The bouts of isolation connected with the Covid-19 pandemic exacerbated the issue, with the British Medical Association declaring a UK mental health crisis at the end of 2022. This media attention has led to acknowledgement of the realities of mental health problems from the government and medical sector, and a recognition that these need to be approached differently to physical ailments when it comes to providing treatment. If you are motivated to be involved in this rapidly changing industry, consider these rewarding business ideas for developing a career in mental health. Become a counsellor Counselling is a broad term, but essentially it is the practice of having impartial conversation with patients about their life experiences with a view to overcoming emotional obstacles and trauma. Training can take three to five years depending on whether you are getting a degree or diploma, and there are many opportunities to specialise both during and after your education. Psychotherapy is a similar field, but this is a more academically focused course that tends to be concerned with long-term or particularly complex mental health issues. You will need a post-graduate qualification and several years of training to become certified.

Enterosgel is a versatile safe drug-free alternative to current anti-diarrhoeal medicines found on pharmacy shelves. Enterosgel is different from other anti-diarrhoeals within this category, as it is suitable for children aged one year and over, so can be taken by the whole family. This intestinal adsorbent can be used for both acute diarrhoea due to gastrointestinal infections and for chronic irritable bowel syndrome with diarrhoea (IBS-D). Why should community pharmacists stock this brand? Unlike anti-diarrhoeals which work by slowing gut motility, Enterosgel is an intestinal adsorbent which physically binds harmful substances from the gut, that can cause diarrhoea and other gastrointestinal symptoms and expels them naturally with the stools. Because it is a medical device not a medicine, has no pharmacological action and is not absorbed by the body, it is a safe option for children and adults and can help reduce the likelihood of side effects which can be an issue with anti-diarrhoeal medicines. Enterosgel has a unique composition of an adsorbent mineral gel based in water, it contains no additional preservatives or additives so is easy to recommend from vegetarians to people with allergies or intolerances. The gel is mixed with water and taken orally in between meals; it is tasteless so well tolerated even by children.

The UK's National Health Service (NHS) has become the first healthcare system in the world to provide a new blood group genotyping test for people with rare inherited blood disorders. From Monday (22 January), thousands of patients suffering from sickle cell disorder and thalassaemia will get access to the world-first 'blood matching' genetic test, which will help reduce their risk of transfusion side effects while offering more personalised care. In England, it is estimated that around 17,000 people are living with sickle cell disorder, with 250 new cases reported each year, and there are about 800 thalassaemia patients, with less than 50 new cases a year. Health Minister Andrea Leadsom said: "Thousands of people living with sickle cell disease and thalassaemia will be eligible for this new world-first blood test which is set to transform their care.

Indian drugmaker Dr Reddy's Laboratories will launch its generic version of Merck's antiviral Covid-19 pill, molnupiravir, and price it at 35 rupees ($0.4693) per capsule, a company spokesperson said on Tuesday (January 4). The overall cost for a patient treated with a 5-day course of 40 capsules of the generic drug, to be sold under brand name 'Molflu', will come up to 1,400 rupees ($18.77). In comparison, the treatment with Merck's pill in the United States costs $700. "Molflu is expected to be available from early next week in pharmacies throughout (India) with particular focus on states with high caseload of Covid-19," the company spokesperson said. India last week gave emergency use approval to along with two vaccines, as the country braces for a possible spike in coronavirus cases due to the rapidly spreading Omicron variant.

'Tepotinib' has been recommended by the National Institute for Health and Care Excellence (NICE) to patients with a specific gene mutation of advanced non-small-cell lung cancer (NSCLC). The new potentially life-extending drug is available from Thursday (14 April). It has been recommended for routine use across the NHS in England through Project Orbis, a programme to review and approve promising cancer drugs helping patients access treatments faster. NICE has published its final appraisal document recommending tepotinib (also known as Tepmetko and produced by company Merck Serono Ltd) as an option for treating advanced NSCLC with METex14 skipping gene alterations in adults. People with METex14 skipping alterations of NSCLC make up between 1-2% of all adults with lung cancer in England. Tepotinib, which requires people to take two tablets once daily, provides a new targeted treatment for adults with METex14 skipping gene alterations. Just over 700 people in England would be eligible to receive tepotinib as either a first or second-line treatment.

A diet supplemented with vitamin D can help support healthy weight loss and reduce fat percentage, a new clinical study revealed. A trial was conducted over a three-month period with 125 overweight and obese Southeastern European Caucasians with vitamin D deficiency or insufficiency. Participants were prescribed vitamin D3 3000 IU/d oral spray supplementation, or a placebo, alongside a calorie-restricted diet programme of 600 kcal less than the total energy expenditure of each individual. The report stated that the group who were prescribed vitamin D witnessed significant improvements in serum 25(OH)D level and a greater reduction in body weight, BMI, and fat percentage in all individuals within this group. The study supported by BetterYou found that with the prevalence of low vitamin D becoming a serious global health problem in all ages, even in areas with natural sun exposure throughout the year, the study shines a light on the importance of vitamin D supplementation.

We cannot deny the benefits and uses of regenerative medicines as they have been so in demand in recent times. One such effective medicine with a lot of potential health benefits is BPS-157. The peptide is thought to be extremely beneficial for those struggling with various neurological or health issues. Another medicine with the same beneficial effects is the Semax peptide. Well, the benefits of both these peptide-based medicines and their other aspects will be discussed in detail in this blog along with answering your question about the BPC-157 buy, Semax effects, and polypeptide. ALL ABOUT BPC-157: BPC-157, a pentadecapeptide consisting of 15 amino acids, is a synthetic peptide that is known for its positive effects on the human body. The peptide is derived from human gastric juice. A protein is present in the human gastric juice through which this peptide is derived and synthesized. It is called a Body Protection Protein as it exerts several therapeutic effects on the human body. Not only have health benefits or therapeutic effects, the peptide has healing and regeneration powers. It also helps in the preventing formation of gastric ulcers. This peptide is of great interest to researchers due to its numerous positive effects and benefits. DOSING LEVELS OF BPC-157: Not much about the dosing levels of BPC-157 has been researched yet but always try to concern the relevant persons before taking the medicine. The dosage of BPC-157 depends on the health and body conditions of the person taking it along with other related factors.

Whether it's the effects of the coronavirus pandemic and those suffering with long Covid, or the financial pressures of rising living costs, these hard times can affect absolutely anyone's mental health. Mental health problems have worsened across all age-groups in the last few years, from lack of social interaction, unexpected bereavements or the significant impact of a physical injury or long-term illness taking its toll on mental wellbeing - these challenging experiences and situations that we face throughout life leave a big strain on the population. Ultimately, there is an urgent need to reduce rising levels of mental ill-health in our society. As a pharmacist with 25 years' experience in healthcare, I feel I have an obligation to my patients to support them with their healthcare needs, and mental health should be treated just the same as physical health. Despite efforts to improve NHS mental health services, patients may still not be receiving the appropriate immediate care as they are often provided with online counselling or an App for long-term support (online support introduced since the pandemic). Community pharmacists are in a unique position to be advocates for patients with mental illness as they are the healthcare professionals' patients see most often. This is a good opportunity for pharmacists to speak to patients face-to-face and give them advice in a more practical way rather than potentially waiting weeks for an GP appointment.